RxDoctor Payments Data

Jeffrey Nakhjavan, DO

Internal Medicine · North Babylon, NYNPI 1578676136

Payments from drug & device makers

$1,255in general payments, 2019–2025

Across 67 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$415
  • Novo Nordisk$151
  • Pfizer$106
  • Inspire Medical Systems, Inc.$89
  • Abbott$69
  • AstraZeneca$61
  • plus $364 from 10 others

What the payments were for

  • Food & beverage$1,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,255 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$997,550
Medicare patients
906
Services billed
16,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$165,080
JardianceEmpagliflozin56$80,134
RybelsusSemaglutide34$66,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$58,078
EliquisApixaban46$57,267
FarxigaDapagliflozin Propanediol46$49,138
MounjaroTirzepatide34$44,827
TrulicityDulaglutide15$28,554
XareltoRivaroxaban19$28,012
CreonLipase/Protease/Amylase11$25,424
LivaloPitavastatin Calcium13$7,394
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$5,761
VascepaIcosapent Ethyl13$4,294
Levothyroxine Sodium240$4,145
Metoprolol Succinate277$4,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$151$231,223148 claims
Boehringer IngelheimJardiance$11$80,13456 claims
Lilly USA, LLCMounjaro, Trulicity$58$73,38149 claims
GSKTrelegy Ellipta$415$58,07856 claims
PfizerEliquis$106$57,26746 claims
AstraZenecaFarxiga$61$49,13846 claims
AbbVieCreon, Synthroid$56$26,92462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in North Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →